Copenhagen, Denmark; August 10, 2016 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today it has entered an agreement to grant Gilead Sciences, Inc. an exclusive license and an option on a second exclusive license, to use the DuoBody® technology platform to create and develop bispecific antibody candidates for a therapeutic …
Tag Archives: duobody technology
August, 2016
February, 2015
-
19 February
Genmab Enters DuoBody Technology Agreement with BioNovion in Immuno-Oncology
Genmab A/S and BioNovion struck a deal to evaluate several DuoBody product candidates targeting immune checkpoints. The companies announced that they have entered into a co-development and commercialization agreement to evaluate the product candidates. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using …